MatsukiyoCocokara & Co - Company Profile
Powered by 
All the sales intelligence you need on MatsukiyoCocokara & Co in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how MatsukiyoCocokara & Co fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with MatsukiyoCocokara & Co.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
MatsukiyoCocokara & Co (MatsukiyoCocokara) is a retailer that operates a chain of drug stores and pharmacies. Its main activities include the operation of drugstores, insurance-covered pharmacies, and dispensing pharmacies, along with a management support business. Its product portfolio includes cosmetics, health care products, medical and pharmaceutical products, general merchandise, and food products. The company offers a range of products and services, including pharmaceuticals, cosmetics, daily necessities, and nursing care equipment. Its other business activities include wholesale trade of pharmaceuticals, and advertising. Notable brands associated with Matsumoto Kiyoshi include Matsukiyo, Matsukiyo LAB, The Retinotime, Argelan, and MQURE. The company's products and services cater to a diverse customer base, including individuals seeking healthcare and beauty products, as well as businesses requiring management support services. The company has a presence across Japan, Taiwan, Thailand, Hong Kong, and Vietnam. MatsukiyoCocokara is headquartered in Bunkyo-Ku, Tokyo, Japan.
Headquarters
Japan
Address
7f, Mk Ochanomizu Bldg., 1-8-2, Yushima, Bunkyo, Tokyo, 113-0034
Website
www.matsukiyococokara.com
Telephone
81 3 68450005
No of Employees
14,293
Industry
Retailing
Ticker Symbol & Exchange
3088 (TYO)
Revenue (2025)
$7.2B
5.3%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
2%
(2025 vs 2024)
Market Cap*
$6.3B
Net Profit Margin (2025)
XYZ
-3.1%
(2025 vs 2024)
* As of and is in US$
MatsukiyoCocokara & Co premium industry data and analytics
Products and Services
| Services | Brands |
|---|---|
| Wholesale | Matsukiyo |
| Retailing | Matsukiyo LAB |
| Advertising Services | The Retinotime |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Plans/Strategy | In September, the company announced plans to launch BEAUSTER Sleeping+ under Matsukiyo LAB and four GABA-based nighttime beauty supplements nationwide and online. |
| 2026 | Plans/Strategy | In September, the company and Alinamin Pharmaceutical Co., Ltd. announced plans to launch Euglena for a Good Night's Sleep. |
| 2026 | Contracts/Agreements | In February, the company entered into an agreement to acquire Universal Drug Co., Ltd, a pharmaceutical company. |
Competitor Comparison
| Key Parameters | MatsukiyoCocokara & Co | Sugi Holdings Co Ltd | Ain Holdings Inc | Create SD Holdings Co Ltd | Pharmarise Holdings Corp |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Bunkyo | Obu-Shi | Sapporo-Shi | Yokohama-Shi | Nakano-Ku |
| State/Province | Tokyo | Aichi | Hokkaido | Kanagawa | Tokyo |
| No. of Employees | 14,293 | 13,417 | 17,332 | 5,478 | 2,031 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Namio Matsumoto | Chairman | Executive Board | 2014 | 83 |
| Takashi Matsuda | Deputy Head - Group Sales Planning; Director | Executive Board | 2022 | 54 |
| Akio Ishibashi | Director; General Manager- Management Planning | Executive Board | 2022 | 62 |
| Kiyoo Matsumoto | Director; President | Executive Board | 2014 | 53 |
| Atsushi Tsukamoto | Director; Vice President | Executive Board | 2021 | 64 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer